Table 3.
Cytogenetic risk | ITIH5 hypermethylation (%) |
---|---|
Total number of patients (n = 104) | 14.4% (15/104) |
Favorable risk (n = 16) | 18.8% (3/16) |
inv(16) (n = 11) | 27.3% (3/11) |
t(8;21) (n = 5) | 0% |
Intermediate risk (n = 60) | 11.7% (7/60) |
Unfavorable risk (n = 14) | 7.1% (1/14) |
Karyotype n.a. (n = 14) | 28.6% (4/14) |
n.a. not available